CONFLICT OF INTEREST
ONCOLOGY
KG has received lecture fees or honoraria from Eli Lilly Japan K.K., Chugai Pharmaceutical Co., Ltd., Amgen Inc., and Takeda Pharmaceutical Co., Ltd. and research funds from Amgen Inc., AstraZeneca K.K., Boehringer Ingelheim Japan, Inc., Bristol‐Myers Squibb K.K., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., Haihe Biopharma Co., Ltd., Ignyta, Inc., Janssen Pharmaceutical K.K., Kissei Pharmaceutica Co., Ltd., Kyowa Kirin Co., Ltd., Life Technologies Japan Ltd., Loxo Oncology, Inc., Medical & Biological Laboratories Co., Ltd., Merck Biopharma Co., Ltd., Merus N.V., MSD K.K., NEC Corporation., Ono Pharmaceutical Co., Ltd., Pfizer Japan Inc., Sumitomo Dainippon Pharma Co., Ltd., Spectrum Pharmaceuticals, Inc., Sysmex Corporation., Taiho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., and Turning Point Therapeutics, Inc. YS has received research funds from Chugai Pharma. HM has received lecture fees or honoraria from AstraZeneca and Chugai Pharma. HH has received lecture fees or honoraria from AstraZeneca, MSD, Eli Lilly, Ono, BMS, Chugai, Roche, Kyowa‐Kirin, and Novartis; and has participated on Advisory Boards for AstraZeneca, Eli Lilly, Chugai, Roche, Ono, BMS, and MSD. MT has received lecture fees or honoraria from Chugai Pharmaceutical Co. Ltd., AstraZeneca K.K., Bristol‐Myers Squibb, Novartis Pharma K.K., and Ono Pharmaceutical Co. Ltd. MN has received research funds from Ono Pharmaceutical, Bristol‐Myers Squibb, Pfizer, Chugai Pharmaceutical, Eli Lilly. JM has received annual value of remuneration from Daiichi Sankyo Inc.KG is an Associate Editor of 